AMILOR: Amiloride in Nephrotic Syndrome

University Hospital Tuebingen (Other)
Overall Status
Recruiting ID

Study Details

Study Description

Brief Summary

The AMILOR study compares treatment of edema in nephrotic syndrome with Amiloride vs. Furosemide.

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

The monocenter randomized-controlled AMILOR trial investigates the efficacy of the ENaC blocker amiloride in reducing edema in nephrotic syndrome compared with standard therapy with the loop diuretic furosemide.

Patients with acute nephrotic syndrome are randomized to receive amiloride (starting dose 5 mg) or furosemide (starting dose 40 mg) for 16 days. The target number of patients is n = 18 per arm. Exclusion criteria include GFR <30ml/min/1.73m², AKIN 1 and 2, hypotension, hyper-/ hypokalemia, and hyponatremia. Overhydration is quantified by bioimpedance spectroscopy. Depending on the course of overhydration, dose adjustments (day 2, 5, 8, 12) or addition of HCT (day 8) are performed during the course of the study.

Primary endpoint is decrease in overhydration at day 8, secondary endpoints include decrease in overhydration at day 16, as well as body weight, edema volume, blood pressure, urine volume, natriuresis at day 8 and 16, and need for dose adjustments and co-medication with HCT. Plasma potassium, sodium, and creatinine concentrations are measured as safety parameters.

Study Design

Study Type:
Anticipated Enrollment :
36 participants
Intervention Model:
Parallel Assignment
None (Open Label)
Primary Purpose:
Official Title:
Randomized, Controlled Interventional Trial to Investigate the Efficacy of Amiloride for the Treatment of Edema in Human Nephrotic Syndrome
Actual Study Start Date :
Jun 8, 2020
Anticipated Primary Completion Date :
Jun 8, 2023
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Amiloride

Treatment wirh Amiloride, start dose 5 mg

Drug: Amiloride
Treatment with amiloride, start dose 5 mg

Active Comparator: Furosemide

Treatment with Furosemide, start dose 40 mg

Drug: Furosemide
Treatment with furosemide, start dose 40 mg

Outcome Measures

Primary Outcome Measures

  1. Decrease of overhydration [8 days]

    Decrease of overhydration (OH) measured by bioimpedance spectroscopy

Secondary Outcome Measures

  1. Decrease of overhydration [16 days]

    Decrease of overhydration (OH) measured by bioimpedance spectroscopy

  2. Decrease of body weight [8 and 16 days]

    Decrease of body weight

  3. Decrease of edema cercumference [8 and 16 days]

    Decrease of edema cercumference, measured at the lower leg

  4. Decrease of blood pressure [8 and 16 days]

    Decrease of systolic and diastolic blood pressure

  5. Increase of urine volume and natriuresis [8 and 16 days]

    Increase of urine volume and natriuresis, measured in 24 hours collected urine

  6. Course of plasma renin activity and serum aldosterone concentration [8 and 16 days]

    Course of plasma renin activity and serum aldosterone concentration, measured in blood samples

  7. Changes of dose of study medication and need for co-medication [8 and 16 days]

    Number of required changes of dose of study medication and need for co-medication with HCT

  8. Occurrence of adverse events [16 days]

    Occurrence of adverse events

Eligibility Criteria


Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  1. Acute nephrotic syndrome with proteinuria > 3 g/day and formation of edema.

  2. Age ≥ 18 years at the time of signing the informed consent.

  3. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures.

  4. Ability to adhere to the study visit schedule and other protocol requirements.

  5. Use of adequate thrombosis prophylaxis due to the increased risk of thrombosis in nephrotic syndrome and the expected fluctuations in volume balance during study participation.

  6. Subject (male or female) is willing to use highly effective methods of contraception according to the "Clinical trial fertility group" recommendations.

  7. Female Patients of childbearing potential (WOCBP) must agree to pregnancy testing before inclusion in the study.

  8. Female Patients must agree to abstain from breastfeeding during study participation and 28 days after study drug discontinuation.

  9. All subjects must agree not to share medication.

Exclusion Criteria:
  1. Severe reduction of kidney function: Creatinine clearance or calculated GFR < 30 mL/min/1.73m² or acute kidney injury KDIGO stage 2 or 3 or anuria.

  2. Hypovolemia or dehydration.

  3. Uncontrolled diabetes mellitus.

  4. Hypotension, systolic blood pressure < 90 mmHg.

  5. Hyperkalemia, plasma potassium concentration > 4.8 mmol/l.

  6. Hypokalemia, plasma potassium concentration < 3.3 mmol/l.

  7. Hyponatremia, plasma sodium concentration < 128 mmol/l.

  8. Hypercalcemia, ionized calcium > 2.0 mmol/l or total albumin corrected calcium > 3.0 mmol/l.

  9. Signs of cardiac decompensation (orthopnoe, dyspnoe NYHA IV).

  10. Hepatic coma or precoma.

  11. Symptoms of gout.

  12. Current therapy with potassium-sparing diuretics (e.g. spironolactone) or potassium supplements.

  13. Women during pregnancy and lactation.

  14. History of hypersensitivity to the investigational medicinal product, comparator or co-medication or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product, comparator or co-medication.

  15. Any other clinical condition that would jeopardize the patient's safety while participating in this clinical trial.

  16. Active participation in other clinical trials or observation period of competing trials.

Contacts and Locations


Site City State Country Postal Code
1 University Hospital Tuebingen Tuebingen Baden-Wuerttemberg Germany 72076

Sponsors and Collaborators

  • University Hospital Tuebingen


  • Principal Investigator: Ferruh Artunc, Prof., MD, University Hospital Tuebingen

Study Documents (Full-Text)

None provided.

More Information

Additional Information:


Responsible Party:
Dr. Anja Schork, Clinincal Investigator, Project management, University Hospital Tuebingen Identifier:
Other Study ID Numbers:
  • AmiloridNS-01
  • 2019-002607-18
First Posted:
Oct 15, 2021
Last Update Posted:
Oct 15, 2021
Last Verified:
Oct 1, 2021
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Keywords provided by Dr. Anja Schork, Clinincal Investigator, Project management, University Hospital Tuebingen
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 15, 2021